60 Degrees Pharmaceuticals to report babesiosis trial data in January 2027

October 6, 2026 8:10 AM

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) said it will conclude enrollment in its clinical study of tafenoquine in hospitalized babesiosis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found